Tailoring endocrine therapy in early breast cancer: prolonged duration and potential drawbacks

Research output: ThesisDoctoral ThesisInternal

141 Downloads (Pure)

Abstract

This dissertation focuses on the hormonal treatment of postmenopausal women with early-stage breast cancer, with the focus on the question what the optimal duration of this treatment is and what the potential side effects are. We have concluded that prolonging adjuvant hormonal therapy with an aromatase inhibitor from 3 to 6 years, after 2-3 years of tamoxifen treatment, should only be considered if there is a high risk of disease recurrence, for example in the presence of regional lymph node metastases. The second part of this thesis focuses on the treatment of a specific subgroup of women with breast cancer who have become postmenopausal as a result of chemotherapy. The third part focuses on the development of bone density during hormonal therapy.
Original languageEnglish
Awarding Institution
  • Maastricht University
Supervisors/Advisors
  • Tjan - Heijnen, Vivianne, Supervisor
  • Peer, P.G.M., Advisor, External person
Award date31 Oct 2019
Place of PublicationMaastricht
Publisher
Print ISBNs9789463754385
DOIs
Publication statusPublished - 2019

Keywords

  • Early stage breast cancer
  • prolonged hormone therapy
  • Aromatase inhibitor
  • Tamoxifen
  • Osteoporosis
  • chemotherapy induced ovarian failure

Cite this